Stockscreener 앱 받기
8.03
1.47%
-0.12
전일 마감가:
$8.15
열려 있는:
$8.18
하루 거래량:
37,966
Relative Volume:
0.12
시가총액:
$74.21M
수익:
-
순이익/손실:
$-6.42M
주가수익비율:
-1.4336
EPS:
-5.6013
순현금흐름:
$-7.45M
1주 성능:
-6.84%
1개월 성능:
-9.27%
6개월 성능:
-5.47%
1년 성능:
-40.52%
1일 변동 폭
$7.85
$8.18
1주일 범위
$7.85
$9.66
52주 변동 폭
$1.80
$16.94
Cervomed Inc Stock (CRVO) Company Profile
명칭
Cervomed Inc
전화
(617) 744-4400
주소
20 PARK PLAZA, BOSTON
CRVO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRVO
Cervomed Inc
|
8.02 | 75.41M | 0 | -6.42M | -7.45M | -5.6013 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.62 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
472.68 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
552.20 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
809.14 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.45 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-13 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2024-12-17 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-12-11 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2024-12-11 | 다운그레이드 | Morgan Stanley | Overweight → Underweight |
| 2024-12-10 | 다운그레이드 | D. Boral Capital | Buy → Hold |
| 2024-12-06 | 개시 | ROTH MKM | Buy |
| 2024-12-05 | 개시 | H.C. Wainwright | Buy |
| 2024-09-18 | 개시 | Chardan Capital Markets | Buy |
| 2024-07-26 | 개시 | Morgan Stanley | Overweight |
| 2024-02-15 | 개시 | Canaccord Genuity | Buy |
| 2020-11-17 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2018-03-21 | 개시 | H.C. Wainwright | Buy |
모두보기
Cervomed Inc 주식(CRVO)의 최신 뉴스
Will CervoMed Inc. stock reach all time highs in 2025Market Rally & Reliable Breakout Forecasts - newser.com
Statistical indicators supporting CervoMed Inc.’s strengthOptions Play & Risk Controlled Stock Pick Alerts - newser.com
Trend analysis for CervoMed Inc. this weekTrade Entry Report & Low Drawdown Momentum Trade Ideas - newser.com
Analyzing recovery setups for CervoMed Inc. investors2025 Risk Factors & AI Based Trade Execution Alerts - newser.com
Is CervoMed Inc. a candidate for recovery playJobs Report & Free Technical Pattern Based Buy Signals - newser.com
What to do if you’re stuck in CervoMed Inc.2025 Momentum Check & Community Supported Trade Ideas - newser.com
Does CervoMed Inc. stock trade at a discount to peersIPO Watch & Advanced Swing Trade Entry Plans - newser.com
How to interpret RSI for CervoMed Inc. stockMarket Volume Summary & Stepwise Entry/Exit Trade Alerts - newser.com
Will CervoMed Inc. outperform the market2025 Earnings Impact & Low Volatility Stock Recommendations - newser.com
Using data tools to time your CervoMed Inc. exitJuly 2025 Selloffs & High Yield Equity Trading Tips - newser.com
Advanced analytics toolkit walkthrough for CervoMed Inc.2025 Geopolitical Influence & Long Hold Capital Preservation Plans - newser.com
CervoMed (NASDAQ:CRVO) Receives Sell (D-) Rating from Weiss Ratings - MarketBeat
Why CervoMed Inc. stock is rated strong buyShare Buyback & Low Drawdown Momentum Ideas - newser.com
CervoMed Unveils Promising Phase 2b Trial Results - TipRanks
CervoMed Drug Cut Dementia Progression Risk By 75% In Trial - inkl
CervoMed shares jump after strong results in dementia drug trial - MSN
CervoMed stock jumps after new positive dementia drug results - Business Upturn
CervoMed stock soars after positive dementia treatment trial data - Investing.com
CervoMed Says Neflamapimod Shows Effective in Treating Dementia with Lewy Bodies Without Alzheimer's Overlap - MarketScreener
CervoMed (CRVO) Reveals Promising Phase 2b Trial Data for Dement - GuruFocus
CervoMed Inc. Reports Promising Phase 2b Trial Results for Neflamapimod in Dementia with Lewy Bodies - Quiver Quantitative
1.12‑pt CDR‑SB gain; 50% GFAP drop — CervoMed Phase 2b RewinD‑LB data show clinical–biomarker correlation - Stock Titan
CervoMed appoints Matthew Winton as chief commercial and business officer By Investing.com - Investing.com Canada
CervoMed Appoints Matthew Winton, Ph.D., as Chief Commercial and Business Officer - GlobeNewswire
CervoMed Inc. Appoints Matthew Winton as Chief Commercial and Business Officer - MarketScreener
CervoMed appoints Matthew Winton as chief commercial and business officer - Investing.com
CervoMed appoints Matthew Winton, Ph.D., as chief commercial and business officer - MarketScreener
75K-option grant: CervoMed names Matthew Winton Chief Commercial & Business Officer, readies for Phase 3 - Stock Titan
CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference - Sahm
Applying chart zones and confluence areas to CervoMed Inc.Trade Volume Summary & Daily Chart Pattern Signals - newser.com
Will CervoMed Inc. stock go up soon2025 Price Action Summary & Risk Adjusted Buy/Sell Alerts - newser.com
Will CervoMed Inc. (DP8) stock keep high P E multiples2025 Price Action Summary & Step-by-Step Trade Execution Guides - newser.com
Short Interest in CervoMed Inc. (NASDAQ:CRVO) Decreases By 31.7% - MarketBeat
What drives CervoMed Inc stock priceEarnings Revision Updates & Free Stock Education Platform for New Investors - earlytimes.in
How CervoMed Inc. (DP8) stock compares with market leaders2025 Trade Ideas & Consistent Growth Equity Picks - newser.com
Can a trend reversal in CervoMed Inc. lead to recoveryJuly 2025 Setups & Expert-Curated Trade Recommendations - newser.com
Is CervoMed Inc. stock a buy in volatile markets2025 Dividend Review & Short-Term High Return Ideas - newser.com
Live market analysis of CervoMed Inc.Market Risk Analysis & Free Real-Time Market Sentiment Alerts - newser.com
Cervomed Inc (CRVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.10%
자본화:
|
볼륨(24시간):